Posted by Michael Wonder on 07 Sep 2020
SMC accepts Spravato (esketamine) nasal spray for use in adults with treatment-resistant major depressive disorder in Scotland
7 September 2020 - SMC acceptance comes less than a week after second rejection by NICE.
Janssen welcomes the SMC decision to accept Spravato (esketamine) nasal spray for use within NHS Scotland in combination with a selective serotonin re-uptake inhibitor or serotonin-norepinephrine re-uptake inhibitor, for adults with treatment-resistant major depressive disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.
The SMC made its decision based on data from the robust Phase 3 clinical trial programme evaluating the safety and efficacy of esketamine in patients with treatment-resistant depression.
